KemPharm Inc

PROVEN MEDICINES ... SAFER THERAPIES

News/events

Press Releases

10/26/2011KemPharm, Inc. Expands Pain Therapy Pipeline with Discovery of KP511
8/30/2011KemPharm, Inc. Expands ADHD Pipeline with Discovery of KP415
5/24/2011KemPharm, Inc. Announces Positive Results from Phase 1 Trial of KP201 for Pain
4/25/2011KemPharm, Inc. Announces Plans to Launch KP106 as First Oral Film Dosage Form for ADHD
3/1/2011KemPharm, Inc. Files Antitrust and Other Counterclaims against Shire LLC
2/22/2011KemPharm, Inc. Announces Initiation of Phase 1 Trial of KP201 for Pain
8/25/2010KemPharm, Inc. Receives Notice of Issuance from USPTO on Second Patent Protecting Company’s ADHD Prodrug Technology
8/16/2010KemPharm, Inc. Receives Notice of Issuance From USPTO on Patent Protecting Company's ADHD Prodrug Technology
6/23/2010KemPharm, Inc. Appoints Todd Johnson, Ph.D. as Chief Commercial Officer
5/18/2010KemPharm, Inc. Announces Entering Into an Exclusive Supply Agreement With Johnson Matthey Inc. for KP201
1/11/2010KemPharm, Inc. Announces Positive Results from Phase 1 Trial of KP106 for ADHD
10/22/2009KemPharm, Inc. Announces Initiation of Phase 1 Trial of KP106 for ADHD
9/16/2009KemPharm, Inc. Expands Prodrug Pipeline with Candidate for Treatment of Pain and Closes Series B Financing

KemPharm News

4/6/2010The Technology Association of Iowa (TAI) Announces the 2010 Prometheus Award Winners
11/11/2009KemPharm's Vice President of Corporate Affairs honored with Iowa's Women of Innovation Award
9/9/2009DeWaay Backs Consumer Health Advisers From Debut VC Fund
8/15/2009DeWaay launches $10 million venture fund
1/21/2009I-Bank Taps Debut Fund For KemPharm
11/3/2008Investing outside the box

Recent/Upcoming Events

January 10-13, 2011JP Morgan's 29th Annual Healthcare Conference 2011
March 14-16, 2011BioNetwork East
March 30 - April 1, 2011BIO-Windhover - Pharmaceutical Strategic Outlook